Lv1
30 积分 2025-03-12 加入
The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif
1个月前
已完结
Advances in LAG3 cancer immunotherapeutics
1个月前
已完结
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL
1个月前
已完结
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL
1个月前
已关闭
Targeting of nanoparticles: folate receptor
1个月前
已完结
皖公网安备34019202002308
